The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

Novo Nordisk carries a Zacks Rank #5 (Strong Sell), whereas Amgen carries a Zacks Rank #3 (Hold) at present, which makes AMGN ...

Now, it’s worth noting Stock Advisor’s total average return is 975 % — a market-crushing outperformance compared to 193% for ...

Novo Nordisk A/S (NYSE: NVO) is making headlines as a leading player in the weight-loss drug market, primarily due to its blockbuster medications, Ozempic and Wegovy. With projected sales reaching $17 ...

U.S. stock futures signal a subdued start to trading in the final full session before Christmas, as investors await fresh data on the health of the U.S. economy. Space-related stocks are under ...

Tesla’s sales across the European Union, the Euro Free Trade Association and the UK dropped 11.8% year-on-year to 22,801 units in November, according to data released Tuesday by the European ...

Dec 23 (Reuters) - European shares ‌were ​muted on ‌Tuesday as healthcare sector gains powered ​by heavyweight Novo Nordisk clinching U.S. ‍approval of its weight ​loss pill were offset ​by ⁠losses in ...